Br ϕ nsted acid catalyzed one-pot condensation of β -naphthol, aldehyde and active methylene substrate: Synthesis of naphthopyrans

P Srihari*, B Ganganna, K Rajendraprasad, Dinesh C Bhunia & J S Yadav

Division of Natural Products Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad 500 607, India

E-mail: srihari@iict.res.in

Received 27 May 2011; accepted (revised) 7 October 2011

An efficient one-pot condensation of β -naphthol, aldehyde and active methylene substrate is achieved using catalytic amount of phosphomolybdic acid. This multi-component reaction resulted in the synthesis of several naphthopyran derivatives in good yields.


Keywords: Aldehyde, multicomponent, benzopyrans, Brønsted acid, Lewis acid

Multicomponent reactions (MCR) continue to attract significant interest due to an important role in the preparation of structurally diverse chemical structures¹. Benzopyran and benzopyran derived molecules display potent biological and pharmacological activities². Similarly, naphthopyrans, the polyfunctionalized benzopyrans have attracted considerable attention due to their interesting photochromic properties³ and also their presence in numerous natural products which exhibit potent mutagenic and cytotoxic⁴, anticancer⁵ and antiproliferative⁶ activities. Even though there are several procedures reported for their synthesis involving Lewis acids^{7a,b}, to the best of the knowledge there is only one procedure available involving Brønsted acid^{7c} catalyzed reaction. In continuation to efforts on exploring the Brønsted acid, phosphormolybdic acid (PMA) as a reagent/catalyst for several organic transformations⁸, it has recently been demonstrated that PMA in combination with SiO₂ can be utilized for multicomponent reactions, wherein new indole derivatives are obtained⁹. Herein is described the synthesis of naphthopyrans by one-pot condensation of β -naphthol, aldehyde and active methylene substrate catalyzed by phosphomolybdic acid (Scheme I).

Results and Discussion

Initially, a reaction of anisaldehyde, acetylacetone and β -naphthol was carried out in the presence of PMA-SiO₂ in CH₂Cl₂ at RT. After refluxing the reaction mixture for 12 hr, all the starting materials were consumed to result in a new single product formation. The product was isolated and characterized as the naphthopyran derivative by NMR analysis and also by comparing the data from earlier literature. Interestingly, when PMA alone was used, the reaction was completed in 5 hr (Table I, entry 1). This encouraged the efforts for optimizing the reaction conditions. To achieve this goal, a similar transformation was attempted with different concentrations of PMA (0.05, 0.1, 0.5 and 1.0 eq.). It was observed that the concentration of either 0.1 eq. or 0.5 eq. gave similar results with respect to yield. Similarly, when different solvents such as DMF, DCE, CH₃CN and MeOH were employed, the reaction did not proceed in DMF and MeOH, whereas the reaction proceeds slowly in CH₃CN. However, the reaction in DCE was found to the best in terms of reaction time and yield. Parallely, Lewis acids such as I₂, NbCl₅ and FeCl₃ which had been utilized earlier for other organic transformations were also screened and found that in the case of I2 and FeCl3 uncharacterized by-products are formed and in the case of NbCl₅, the product is formed in 70% yield along with uncharacterized by-product. When pTSA was tried, the formation of 50% product was observed along with uncharacterized by-products. The results were encouraging enough to proceed ahead with Brønsted acid PMA to investigate further scope and generality of this reaction.

Thus, with the optimized conditions, other combinations of aldehydes and active methylene substrates were explored with β -naphthol (**Tables I**



Scheme I — Synthesis of naphthopyrans

and **II**). Both electron rich aldehydes and electron poor aldehydes responded well for this reaction and the yields were slightly higher for electron rich aldehydes. Active methylene substrate such as acetyl acetone and ethyl acetoacetate or methyl acetoacetate responded well and in both the cases only single product was isolated. No lactone formation was observed with ethyl acetoacetate or methyl acetoacetate. When a reaction was attempted with dimedone (cyclic diketone with active methylene substrate), it was a pleasure to find that the reaction worked well in this case also to get the corresponding naphthopyran derivative (Table II, entry no.16, product 16a). This protocol is also amenable for large scale synthesis and is well evidenced by a reaction, wherein product **6a** was easily synthesized on 2 g scale with 85% yield in 5 hr.

Mechanistically, the reaction may proceed by two mechanisms, one involving the formation of orthoquinone methide (which results from the reaction of β -naphthol and aldehyde), its entrapment with active methylene substrate via Michael addition (Scheme II) followed by ring closure and dehydration¹⁰ or the second in which condensation between an aldehyde and active methylene compound occurs to produce the Knoevenagel product, followed by Michael type of addition, cyclization and dehydration. Since no intermediate (Knoevenagel product) could be observed and could isolate directly the naphthopyran derivative, the former mechanism fits for this reaction.

However, when a reaction of Knoevenagel product and β -naphthol in presence of PMA was performed (**Scheme III**), the formation of a similar product in good yield could be observed. Thus the possibility of the latter mechanism cannot be ruled out. At this stage, no attempts were made to further study the detailed mechanism involved.

In conclusion, naphthopyran derivatives have been synthesized involving a one pot multicomponent condensation reaction of aldehyde, active methylene substrate and β -naphthol catalyzed by Br ϕ nsted acid PMA. The reaction happens to be atom economic and easily amicable for large scale synthesis involving very small amounts of Br ϕ nsted acid catalyst. Investigation to explore these scaffolds for biological activity is currently under progress.

Experimental Section.

Representative experimental procedure

To a mixture of β -napthol (1.0 mmol), aldehyde (1.0 mmol), and active methylene substrates (1.0 mmol) was added PMA (0.1 mmol) in dichloroethane (5 mL). The mixture was stirred at 85°C for the given time (**Tables I** and **II**). The progress of the reaction was monitored by TLC. After completion of reaction, the reaction was quenched with saturated aq. NaHCO₃ solution (2 mL). Dichloroethane was removed on rotary evaporator and the residue was extracted with ethyl acetate (2 × 5 mL). The organic layer was separated and washed with brine and dried over anhydrous Na₂SO₄. The solvent was evaporated under reduced pressure and the crude product was purified by silica gel column chromatography to provide the pure product.

1-(1-(4-Methoxyphenyl)-3-methyl-1*H***-benzo[***f***]chromen-2-yl)ethanone, 1a: White solid¹⁰, m.p. 156-58°C; Lit¹⁰ m.p. 156-57°C; R_f = 0.6 (hexane / EtOAc, 9:1); IR(KBr): 1644, 1599, 1509, 1225, 1029, 814, 749 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): \delta 2.37 (s, 3H), 2.47 (s, 3H), 3.68, (s, 3H), 5.60 (s, 1H), 6.69 (d,** *J* **= 8.7 Hz, 2H), 7.19 (d,** *J* **= 8.7 Hz, 2H), 7.25 (t,** *J* **= 4.2 Hz, 1H), 7.30 (dt,** *J* **= 7.9, 0.9 Hz, 1H), 7.43, (dt,** *J* **= 8.3, 1.1 Hz, 1H), 7.69, (d,** *J* **= 8.9 Hz, 1H), 7.74, (d,** *J* **= 7.9 Hz, 1H), 7.99 (d,** *J* **= 8.5 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): \delta 20.3, 30.8, 37.4, 55.0, 113.8 (2 C), 116.8, 116.9, 117.7, 122.9, 124.5, 126.7, 128.5, 129.0, 130.7 (2 C), 131.2 (2 C), 137.3, 147.4, 157.9, 158.3, 198.3; MS(FAB):** *m/z* **344 (M⁺).**

Table I — Synthesis of naphthopyran derivatives												
Entry	Active methylene compound	Aldehyde	2-Naphthol	Product	Reaction time (hr)	Yield ^a (%)	Physical state					
1		CHO OMe	но	OMe OHE Ia	5	85	Solid ¹⁰ (m.p.156- 58 [°] C)					
2		CHO Br	НО	Br O O Za	6	91	Solid(m.p.162- 63°C)					
3	°	CHO NO ₂	но	NO ₂ O J J J a	6	74	Solid(m.p.202- 03°C)					
4		CHO OPh	но	Ph O O H H Aa	6	77	Solid(m.p.125- 26°C)					
5		CHO OMe	но	OMe OHE 5a	5	88	Solid ¹⁰ (m.p.117- 19°C)					
6		CHO	но	6a NO ₂	4	86	Solid ¹⁰ (m.p.130- 32°C)					
7		CHO NO ₂	но	7a	5	75	Solid(m.p.141- 42°C)					
8		CHO CHO OPh	НО	Ph ^O O O O O O O O O O O O O O O O O O O	5	80	Colourless liquid					


Table I — Synthesis of naphthopyran derivatives

^aProducts purified by column chromatography and characterized by IR, ¹H, and ¹³C NMR and mass analysis. Yields calculated after column chromatography.


Table II — Synthesis of naphthopyran derivatives

Table II — Synthesis of naphthopyran derivatives												
Entry	Active methylene compound	Aldehyde	2-Naphthol	Product	Reaction time (sec)	Yield ^a (%)	Physical state					
9		CHO Ph	но	Ph Ph 9a	6	74	Yellow liquid					
10		СНО	но	10a	5	90	Solid (m.p. 122- 24°C)					
11		СНО	но	o 11a	5	76	Colourless liquid					
12		CHO	но	OMe o 12a	6	85	Solid (m.p.152- 53°C)					
13		CHO	но	Ci of the second	5	78	Solid (m.p.139- 40°C)					
14		CHO NO ₂	но	NO ₂ 14a	4	76	Solid (m.p.177- 78°C)					
15		CHO	но	PhO O I5a	5	85	Colourless liquid					
16		CHO	но	Cl Cl Cl Cl Cl Cl Cl Cl Cl Cl Cl Cl Cl C	6	71	Solid (m.p.168- 70°C)					

^aProducts purified by column chromatography and characterized by IR, ¹H, and ¹³C NMR and mass analysis. Yields calculated after column chromatography.



Scheme II — Postulated mechanism for naphthopyran formation



Scheme III — Synthesis of naphthopyrans from Knoevenagel products

1-(1-(4-Bromophenyl)-3-methyl-1*H***-benzo[***f***]chromen-2-yl)ethanone, 2a: White solid, m.p. 162-63°C; R_f = 0.5 (hexane / EtOAc, 9:1); IR(KBr): 1646, 1595, 1318, 1222, 831, 739 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): \delta 2.37 (s, 3H), 2.48 (s, 3H), 5.66 (s, 1H), 7.16 (d,** *J* **= 8.3 Hz, 2H), 7.28 (t,** *J* **= 8.3 Hz, 3H), 7.35 (dt,** *J* **= 7.9, 1.1 Hz, 1H), 7.44 (dt,** *J* **= 8.3, 1.3 Hz, 1H), 7.68-7.79 (m, 2H), 7.92 (d,** *J* **= 8.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): \delta 20.4, 31.1, 37.5, 116.7, 116.8 (2 C), 120.3, 122.7, 124.7, 126.9, 128.5, 128.8, 129.8 (2 C), 130.6, 131.2, 131.4 (2 C), 144.1, 147.5, 158.9, 197.5; MS(FAB):** *m/z* **392 (M⁺).**

1-(3-Methyl-1-(4-nitrophenyl)-1*H*-benzo[*f*]chromen-2-yl)ethanone, **3**a: White solid, m.p. 202-203°C; $R_f = 0.5$ (hexane / EtOAc, 9:1); IR(KBr): 1643, 1595, 1519, 1351, 1223, 829 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 2.42 (s, 3H), 2.53 (s, 3H), 5.87 (s, 1H), 7.30-7.55 (m, 5H), 7.73-7.84 (m, 2H), 7.91 (d, *J* = 8.3 Hz, 1H), 8.03 (d, *J* = 8.9 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃): δ 20.8, 31.4, 37.7, 116.2, 116.5, 116.8, 122.5, 123.6 (2 C), 125.0, 127.2, 128.7, 129.1(2 C), 129.3, 130.5, 131.3, 146.3, 147.6, 152.3, 160.0, 196.9; MS(FAB): *m/z* 360 (M⁺+H).

1-(3-Methyl-1-(3-phenoxyphenyl)-1*H***-benzo**[*f*]**chromen-2-yl)ethanone, 4a**: White solid, m.p. 125-26°C; $R_f = 0.4$ (hexane / EtOAc, 19:1); IR(KBr): 1677, 1578, 1482, 1228, 942, 814, 745 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 2.38 (s, 3H), 2.46 (s, 3H), 5.65 (s, 1H), 6.68 (d, *J* = 8.3 Hz, 1H), 6.89 (d, *J* = 7.7 Hz, 2H), 7.02-7.15 (m, 4H), 7.22-7.33 (m, 3H), 7.34-7.50 (m, 2H), 7.67-7.81 (m, 2H), 8.02 (d, *J* = 8.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 20.3, 30.8, 38.3, 116.3, 116.6, 117.0, 117.1, 118.7 (2 C), 118.8, 122.9, 123.0, 123.1, 124.6, 126.8, 128.5, 128.7, 129.6 (2 C), 129.7, 130.7, 131.2, 147.0, 147.5, 156.9, 157.0, 158.7, 198.1; MS(FAB): *m/z* 406 (M⁺).

Ethyl-1-(4-methoxyphenyl)-3-methyl-1*H***-benzo-[***f***]chromene-2-carboxylate, 5a: White solid¹⁰, m.p.117-19°C; Lit.¹⁰ m.p. 117-19°C; R_f = 0.5 (hexane / EtOAc, 19:1); IR(KBr): 1707, 1509, 1257, 1214, 1065, 1029, 809 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.34 (t,** *J* **= 7.1 Hz, 3H), 2.49 (s, 3H), 3.68 (s, 3H), 4.22 (q,** *J* **= 7.1, 5.8 Hz, 2H), 5.61 (s, 1H), 6.71 (d,** *J* **= 8.7 Hz, 2H), 7.20-7.42 (m, 5H), 7.66-7.80 (m, 2H), 7.96 (d,** *J* **= 8.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 14.3, 19.6, 37.4, 55.1, 60.3, 107.4, 113.5 (2 C), 117.0, 117.3, 123.2, 124.5, 126.7, 128.4, 128.5, 129.3 (2 C), 130.9, 131.2, 137.8, 147.6, 158.0, 159.3, 167.2; MS(FAB):** *m/z* **374 (M⁺).**

Ethyl 1-(4-chlorophenyl)-3-methyl-1*H*-benzo[*f*]chromene-2-carboxylate, 6a: White solid¹⁰, m.p.130-32°C. Lit¹⁰ m.p.130-32°C; $R_f = 0.6$ (hexane / EtOAc, 9:1); IR(KBr): 1686, 1648, 1221, 1089, 1054, 831 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.32 (t, *J* = 6.9 Hz, 3H), 2.50 (s, 3H), 4.21 (q, J = 6.9, 6.0 Hz, 2H), 5.63 (s, 1H), 7.13 (d, J = 8.5 Hz, 2H), 7.22-7.46 (m, 5H), 7.67-7.79 (m, 2H), 7.89 (d, J = 8.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 14.3, 19.6, 37.7, 60.4, 107.1, 116.5, 117.0, 123.0, 124.6, 127.0, 128.3 (2 C), 128.5, 129.0, 129.7 (2 C), 130.7, 131.2, 132.0, 144.0, 147.6, 160.0, 167.0; MS(FAB): m/z 378 (M⁺).

Ethyl 3-methyl-1-(4-nitrophenyl)-1*H***-benzo[***f***]chromene-2-carboxylate, 7a: White solid, m.p.141-42°C; R_f = 0.6 (hexane / EtOAc, 9:1); IR(KBr): 1715, 1519, 1346, 1212, 1061, 827 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.34 (t,** *J* **= 6.9 Hz, 3H), 2.53 (s, 3H), 4.23 (q,** *J* **= 6.9, 7.1 Hz, 2H), 5.77 (s, 1H), 7.28-7.54 (m, 5H), 7.72-7.88 (m, 3H), 8.04 (d,** *J* **= 8.8 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃): δ 14.3, 19.8, 38.3, 60.6, 106.0, 115.6, 117.0, 122.5, 123.5 (2 C), 124.9, 127.1, 128.6, 129.2 (2 C), 129.3, 130.5, 131.3, 146.4, 147.6, 152.6, 160.6, 166.7; MS(FAB):** *m/z* **389 (M⁺).**

Ethyl 3-methyl-1-(3-phenoxyphenyl)-1*H***-benzo-[***f***]chromene-2-carboxylate, 8a: Colourless liquid; R_f = 0.6 (hexane / EtOAc, 9:1); IR(KBr): 1707, 1589, 1484, 1218, 1063, 750 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.29 (t,** *J* **= 7.1 Hz, 3H), 2.50 (s, 3H), 4.19 (q,** *J* **= 6.9, 7.1 Hz, 2H), 5.63 (s, 1H), 6.70 (d,** *J* **= 6.6 Hz, 1H), 6.91 (d,** *J* **= 7.7 Hz, 2H), 6.96-7.14 (m, 4H), 7.22-7.32 (m, 3H), 7.33-7.48 (m, 2H), 7.68-7.80 (m, 2H), 7.93 (d,** *J* **= 8.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 14.3, 19.5, 38.2, 60.4, 96.1, 107.0, 116.7, 117.1, 118.6 (2 C), 119.4, 123.0, 123.3, 124.5, 127.1, 128.5, 128.8, 129.6 (2 C), 131.0, 131.3, 147.5, 147.7, 157.0, 157.3, 159.7, 167.0; MS(FAB):** *m/z* **436 (M⁺).**

3-Methyl-1-styryl-1*H***-benzo[***f***]chromene-2-carboxylic acid ethyl ester, 9a:** Yellow liquid. $R_f = 0.6$ (hexane / EtOAc, 9:1); IR(KBr): 1644, 1220, 1065, 773 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.38 (t, *J* = 7.1 Hz, 3H), 2.51 (s, 3H), 4.30 (q, *J* = 7.1, 12.0 Hz, 2H), 5.30 (d, *J* = 4.9 Hz, 1H), 6.30 (d, *J* = 4.9 Hz, 2H), 7.19-7.27 (m, 5H), 7.38-7.46 (m, 1H), 7.48-7.55 (d, *J* = 8.8 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 1H), 8.04 (d, *J* = 8.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 14.4, 19.6, 35.2, 60.4, 117.1, 123.1, 124.6, 126.3, 126.8, 127.2, 128.3, 128.5, 130.0 (2 C), 131.2 (2 C), 131.3 (2 C), 137.7, 148.0, 147.7, 161.0, 167.2; MS(FAB): *m/z* 370 (M⁺).

Ethyl 3-methyl-1-phenyl-1*H***-benzo**[*f*]**chromene-2-carboxylate**, **10a**: White solid, m.p.122-24°C; R_f = 0.4 (hexane / EtOAc, 9:1) IR(KBr): 1688, 1648, 1223, 1059 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.32 (t, *J* = 7.5 Hz, 3H), 2.49 (s, 3H), 4.19 (q, *J* = 6.7, 7.1 Hz, 2H), 5.59 (s, 1H), 6.99-7.05 (m, 1H), 7.14 (t, *J* = 8.3 Hz, 2H), 7.22-7.40 (m, 5H), 7.67 (t, *J* = 9.8 Hz 2H),

7.89 (d, J = 8.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 14.3, 19.6, 38.3, 60.3, 107.2, 117.0, 117.1, 123.1, 124.5, 126.3, 126.7, 128.2, 128.4, 128.6, 130.0, 131.2 (2C), 145.4, 147.7, 159.6, 167.2; MS(FAB): m/z 344 (M⁺).

Methyl 3-methyl-1-pentyl-1*H*-benzo[*f*]chromene-2carboxylate, 11a: Colourless liquid. $R_f = 0.7$ (hexane / EtOAc, 19:1); IR(KBr): 1714, 1649, 1216, 1079, 813 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 0.77 (t, *J* = 6.9 Hz 3H), 0.88-1.23 (m, 6H), 1.63-1.80 (m, 2H), 2.50 (s, 3H), 3.84 (s, 3H), 4.69 (t, *J* = 4.9 Hz, 1H), 7.18 (d, *J* = 8.8 Hz, 1H), 7.39-7.47 (m, 1H), 7.51-7.58 (m, 1H), 7.69 (d, *J* = 8.8 Hz, 1H), 7.82 (d, *J* = 7.5 Hz, 1H), 8.04 (d, *J* = 8.4 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 14.0, 19.4, 22.5, 24.3, 31.4, 32.0, 36.3, 55.4, 105.4, 116.8, 118.0, 122.7, 124.4, 126.5, 127.7, 128.5, 130.8, 131.2, 148.6, 161.7, 168.1; MS(FAB): m/z 325 (M⁺+1).

Methyl 1-(4-methoxyphenyl)-3-methyl-1*H*-benzo[*f*]chromene-2-carboxylate, 12a: White solid, m.p.152-53°C; $R_f = 0.6$ (hexane / EtOAc, 9:1); IR(KBr): 1686, 1509, 1226, 1062, 748 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 2.49 (s, 3H), 3.67 (s, 3H), 3.76 (s, 3H), 5.61 (s, 1H), 6.71 (d, *J* = 8.6 Hz, 2H), 7.18-7.46 (m, 5H), 7.68-7.79 (m, 2H), 7.95 (d, *J* = 8.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 19.6, 37.3, 51.3, 55.0, 107.3, 113.6 (2 C), 117.1, 117.2, 123.1, 124.5, 126.7, 128.4, 128.5, 129.2 (2 C), 130.8, 131.2, 137.8, 147.6, 158.0, 159.5, 167.7; MS(FAB): *m/z* 360 (M⁺).

1-(4-Chloro-phenyl)-3-methyl-1*H***-benzo[***f***]chromene-2-carboxylicacidmethylester, 13**a: White solid, m.p.139-40°C; R_f = 0.4 (hexane / EtOAc, 9:1); IR(KBr): 1695, 1486, 1224, 1062, 836, 809 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 2.49 (s, 3H), 3.76 (s, 3H), 5.64 (s, 1H), 7.14 (d, *J* = 8.4 Hz, 2H), 7.20-7.46 (m, 5H), 7.74 (t, *J* = 9.4 Hz, 2H), 7.88 (d, *J* = 8.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 19.6, 37.7, 51.4, 106.7, 116.4, 117.0, 123.0, 124.7, 126.9, 128.4, 128.5 (2 C), 128.9, 129.5 (2 C), 130.7, 131.3, 132.1, 144.0, 147.6, 160.1, 167.4; MS(FAB): *m/z* 364 (M⁺).

Methyl 3-methyl-1-(4-nitrophenyl)-1*H*-benzo[*f*]chromene-2-carboxylate, 14a: White solid, m.p.177-78°C; R_f = 0.6 (hexane / EtOAc, 19:1); IR(KBr): 1719, 1518, 1344, 1260, 1214, 1069, 807 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 2.53 (s, 3H), 3.78 (s, 3H), 5.78 (s, 1H), 7.29-7.53 (m, 5H), 7.74-7.87 (m, 3H), 8.05 (d, *J* = 8.6 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃): δ 19.8, 38.3, 51.6, 106.0, 115.6, 117.0, 122.6, 123.7 (2 C), 125.0, 127.2, 128.7, 129.1 (2 C), 129.4, 130.5, 131.4, 146.4, 147.7, 152.5, 161.0, 167.2; MS(FAB): *m/z* 375 (M⁺).

Methyl 3-methyl-1-(3-phenoxyphenyl)-1*H*-benzo[*f*]chromene-2-carboxylate, 15a: Colourless liquid; $R_f = 0.4$ (hexane / EtOAc,19:1); IR(KBr): 1711, 1589, 1484, 1219, 1066, 750 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 2.50 (s, 3H), 3.72 (s, 3H), 5.62 (s, 1H), 6.70 (d, *J* = 7.7 Hz, 1H), 6.88-7.14 (m, 6H), 7.22-7.46 (m, 5H), 7.67-7.79 (m, 2H), 7.92 (d, *J* = 8.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 19.5, 38.1, 51.3, 106.8, 116.7 (2 C), 117.0, 118.6 (2 C), 119.1, 123.0, 123.1, 123.2, 124.6, 126.8, 128.4, 128.8, 129.6 (3 C), 130.8, 131.3, 147.4, 147.6, 156.8, 157.2, 160.1, 167.5; MS(FAB): *m/z* 422 (M⁺).

12-(4-Chlorophenyl)-9,9-dimethyl-8,9,10,12-tetrahydro-benzo[*a*]**xanthen-11-one**, **16a**: White solid, m.p.168-70°C; $R_f = 0.5$ (hexane / EtOAc, 9:1); IR(KBr): 1646, 1372, 1226, 838 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 0.93 (s, 3H), 1.11 (s, 3H), 2.22 (d, *J* = 3.7 Hz, 2H), 2.52 (s, 2H), 5.63 (s, 1H), 7.08-7.14 (m, 2H), 7.20-7.42 (m, 5H), 7.70-7.76 (m, 2H), 7.85 (d, *J* = 8.3 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 27.1, 29.3, 32.1, 34.1, 41.3, 60.0, 114.0, 117.1, 117.2, 123.6, 125.1, 127.2, 128.5, 128.6, 129.2, 129.9, 131.3, 135.5, 132.1, 143.3, 147.9, 164.1, 196.8; MS(FAB): *m/z* 389 (M⁺).

Acknowledgements

BG and DCB thank CSIR, New Delhi for the award of fellowships. PS acknowledges research grant (P 81-113) from Human Resources Research Group, New Delhi through the Council of Scientific and Industrial Research (CSIR) Young Scientist Award Scheme.

References

 (a) Tejedor D & Garcia-Tellado F, *Chem Soc Rev*, 36, 2007, 484; (b) Domling A, *Chem Rev*, 106, 2006, 17; (c) Zhu J & Bienayme H, in *Multicomponent Reactions* (Willey-VCH, Weinheim, Germany), 2005, p468; (d) Ramon D J & Yus M, *Angew Chem Int Ed (Engl)*, 44, 2005, 1602; (e) Simon C, Constantieux T & Rodriguez J, *Eur J Org Chem*, **2004**, 4957; (f) Nair V, Rajesh C, Vinod A U, Bindu S, Sreekanth A R, Mathen J S & Balagopal L, *Acc Chem Res*, 36, **2003**, 899; (g) Ugi I, *Pure Appl Chem*, 73, **2001**, 187.

- 2 (a) Ogundaini A, Farah M, Perera P, Samuelsson G & Bohlin L, J Nat Prod, 59, 1996, 587; (b) Chino M, Nishikawa K, Yamada A, Ohsono M, Sawa T, Hanaoka F, Ishizuka M & Takeuchi T, J Antibiot, 51, 1998, 480; (c) Dell C P, Curr Med Chem, 5, 1998, 179; (d) Andreani L L & Lapi E, Boll Chim Farm, 99, 1960, 583; (e) Bonsignore L, Loy G, Secci D & Calignano A, Eur J Med Chem, 28, 1993, 517.
- 3 (a) Hepworth J D & Heron B M, in *Progress in Heterocyclic Chemistry*, Vol. 17 edited by G Gribble and J Joule (Elsevier, Amsterdam), 2005, p33; (b) Nakatsuji S, *Chem Soc Rev*, 33, 2004, 348; (c) Shilova E A, Pepe G, Samat A & Moustrou C, *Tetrahedron* 64, 2008, 9977; (d) Kumar S, Hernandez D, Hoa B, Lee Y, Yang J S & McCurdy A, *Org Lett*, 10, 2008, 3761; (e) diNunzio M R, Gentili P L, Romani A & Favaro G, *Chem Phy Chem*, 9, 2008, 768; (f) Malic N, Campbell J A & Evans R A, *Macromolecules*, 41, 2008, 1206.
- 4 (a) Varanda E A, Raddi M S G, Dias F L P, Araujo M C S, Gibran S C A, Takahashi C S & Vilegas W, *Teratog Carcinog Mutagen*, 17, **1997**, 85; (b) Hussein A A, Barberena I, Capson T L, Kursar T A, Coley P D, Solis P N & Gupta M P, *J Nat Prod*, 67, **2004**, 451.
- 5 (a) Hollick J J, Golding B T, Hardcastle I R, Martin N, Richardson C, Rigoreau L J M, Smith G C M & Griffin R J, *Bioorg Med Chem Lett*, 13, **2003**, 3083; (b) Moharram S, Zhou A, Wiebe L I & Knaus E E, *J Med Chem*, 47, **2004**, 1840; (c) Krishnan P & Bastow K F, *Biochem Pharmacol*, 60, **2000**, 1367.
- 6 Wood D L, Panda D, Wiernicki T R, Wilson L, Jordan M A & Singh J P, *Mol Pharmacol*, 52, **1997**, 437.
- 7 (a) Li J J, Tang W Y, Lu L & Su W K, *Tetrahedron Lett*, 49, 2008, 7117; (b) Fan J & Wang Z, *Chem Commun*, 2008, 5381; (c) Khurana J M & Magoo D, *Tetrahedron Lett*, 50, 2009, 4777.
- 8 (a) Srihari P, Reddy J S S, Bhunia D C, Mandal S S & Yadav J S, *Synth Commun*, 38, 2008, 1448; (b) Srihari P, Reddy J S S, Mandal S S, Satyanarayana K & Yadav J S, *Synthesis*, 2008, 1853; (c) Srihari P, Mandal S S, Reddy J S S, Srinivasa Rao R & Yadav J S, *Chin Chem Lett*, 2008, 767; (d) Srihari P, Mandal S S, Reddy J S S, Srinivasa Rao R & Yadav J S, *Chin Chem Lett*, 19, 2008, 771.
- 9 Srihari P, Singh V K, Bhunia D C & Yadav J S, *Tetrahedron Lett*, 50, **2009**, 3763.
- 10 Mashraqui S H, Patil M B, Mistry H D, Ghadigaonkar S & Meetsma A, *Chem Lett*, 33, 2004, 1058.